- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02451384
According CTC to Compare the Influences of Different Methods to Remove the PDAC
June 28, 2015 updated by: Wenhui Lou, Shanghai Zhongshan Hospital
To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells
Acccording circulating tumor cells to compare the differences of different methods(routine method、no-touch principle method、laparoscopy method) to remove the ductal adenocarcinoma of pancreatic body and tail.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Zhongshan Hospital Affiliated to Fudan University
-
Shanghai, Shanghai, China, 200032
- Not yet recruiting
- Genaral surgery department of Zhongshan Hospital, Fudan University
-
Contact:
- W H Lou, PhD
- Phone Number: +8618616881868
- Email: lou.wenhui@zs-hospital.sh.cn
-
Contact:
- X F Xu, PhD
- Phone Number: +8613061626568
- Email: xu.xuefeng@zss-hospital.sh.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ductal adenocarcinoma of pancreatic body and tail
- Tumor can be removed
- No other tumors and without liver metastases
- Age from 18 to 80 years old
Exclusion Criteria:
- Neoplasms with other sites of the pancreas
- With other tumors of any other sites
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: routine surgery
In this arm the patients will be performed routine surgery to remove the tumors.
And then we compare their circulating tumor cell countings in the pre and post-operation.
|
To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
|
|
EXPERIMENTAL: no-touch surgery
In this arm the patients will be performed no-touch surgery to remove the tumors.
And then we compare their circulating tumor cells countings in the pre and post-operation.
|
|
|
EXPERIMENTAL: laparoscopy surgery
In this arm the patients will be performed laparoscopy surgery to remove the tumors.
And then we compare their circulating tumor cells countings in the pre and post-operation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the changes of CTCs countings between the pre and post-operation in each arm
Time Frame: Within 1 week after the surgeries are completed in any arm
|
Within 1 week after the surgeries are completed in any arm
|
|
the changes of CTCs countings between the pre and post-operation among the arms
Time Frame: Within 2 weeks after the surgeies are all completed
|
Within 2 weeks after the surgeies are all completed
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (ANTICIPATED)
October 1, 2016
Study Completion (ANTICIPATED)
December 1, 2016
Study Registration Dates
First Submitted
May 14, 2015
First Submitted That Met QC Criteria
May 21, 2015
First Posted (ESTIMATE)
May 22, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
June 30, 2015
Last Update Submitted That Met QC Criteria
June 28, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neoplastic Processes
- Pancreatic Diseases
- Neoplasm Metastasis
- Neoplasms, Ductal, Lobular, and Medullary
- Pancreatic Neoplasms
- Carcinoma, Ductal
- Neoplastic Cells, Circulating
- Carcinoma, Pancreatic Ductal
Other Study ID Numbers
- B2015-010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Pancreatic Ductal
-
SOFIECompletedFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Massachusetts General HospitalTerminatedResectable Pancreatic Cancer | Pancreatic Ductal CarcinomaUnited States
-
ProDa BioTech, LLCUniversity of Alabama at Birmingham; Georgia State UniversityRecruitingPancreatic Ductal Adenocarcinoma (PDAC)United States
-
Peking Union Medical College HospitalRecruiting
-
Halozyme TherapeuticsTerminatedPancreatic Ductal CarcinomaKorea, Republic of, United States, Taiwan, United Kingdom, Israel, France, Germany, Netherlands, Canada, Spain, Australia, Brazil, Belgium, Croatia, Czechia, Denmark, Estonia, Hungary, Italy, Latvia, Lithuania, Poland
-
University Health Network, TorontoNot yet recruitingAdvanced Cancer | Pancreatic Ductal Carcinoma | Epithelial TumorCanada
-
Corcept TherapeuticsRecruitingAdenocarcinoma | Carcinoma, Pancreatic DuctalUnited States
-
University Hospital TuebingenTechnical University of Munich; University Hospital Freiburg; Wuerzburg University... and other collaboratorsNot yet recruitingPancreatic Neoplasms | Carcinoma, Pancreatic Ductal
-
University of MiamiNational Cancer Institute (NCI); BillionToOne, IncRecruitingPancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
Allist Pharmaceuticals, Inc.RecruitingColorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12CChina
Clinical Trials on laparoscopic surgery
-
University Hospital, GrenobleCompleted
-
Zunyi Medical CollegeUnknownColorectal CancerChina
-
Ruijin HospitalRecruiting
-
First Affiliated Hospital Xi'an Jiaotong UniversityAir Force Military Medical University, ChinaUnknownGastrointestinal Stromal TumorsChina
-
Shoichi Fujii, MD, PhDUnknownColorectal CancerJapan
-
Fujian Medical UniversityCompleted
-
Fujian Medical UniversityEnrolling by invitation
-
The Second Affiliated Hospital of Chongqing Medical...UnknownLaparoscopic SurgeryChina
-
University Hospital TuebingenInstitute of Occupational and Social Medicine and Health Services Research...CompletedMusculoskeletal Diseases or ConditionsGermany
-
Ruijin HospitalCompleted